iOrganBio, a company specializing in intelligent cell manufacturing, announced today the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin, a prominent figure in stem cell biology and translational neuroscience, brings extensive experience in neurodegenerative disease research and therapeutic development to the company's advisory panel.
Dr. Rubin is Co-Director and Principal Faculty of the Harvard Stem Cell Institute and a Professor in Harvard's Department of Stem Cell and Regenerative Biology. His research has advanced the understanding of blood-brain barrier biology, neural stem cell differentiation, and disease modeling using patient-derived induced pluripotent stem cells. He has contributed to the development of therapeutic candidates for Parkinson's disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA).
According to iOrganBio, Dr. Rubin's appointment will be instrumental in expanding the company's platform for neurological applications. The company's CellForge platform combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency. This technology enables scalable production for disease modeling, drug discovery, and cell therapy development.
“We are thrilled to welcome Dr. Rubin to our Scientific Advisory Board,” said a spokesperson for iOrganBio. “His deep expertise in stem cell biology and neurodegenerative diseases will be invaluable as we advance our platform to address complex neurological conditions.”
Dr. Rubin expressed enthusiasm about joining the advisory board, stating that iOrganBio's approach to cell manufacturing could accelerate progress in understanding and treating neurological disorders. The full announcement, including downloadable images and bios, is available here.
iOrganBio's CellForge platform is powered by the company's functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process aims to deliver accuracy, efficiency, and quality for partners in disease modeling, regenerative medicine, and drug development.
The appointment underscores iOrganBio's commitment to advancing cell manufacturing for therapeutic applications, particularly in neurology. As the company continues to develop its platform, Dr. Rubin's guidance is expected to help shape strategies for tackling some of the most challenging neurodegenerative diseases.
